Results of clinical renal transplantation in 15 dogs using triple drug immunosuppressive therapy.
OBJECTIVE
To evaluate outcome of renal transplantation in dogs administered cyclosporine, azathioprine, and prednisolone immunosuppression.


METHODS
Prospective clinical study.


METHODS
Fifteen dogs with chronic renal failure.


RESULTS
Nine dogs died within 1 month of surgery; 5 died from complications associated with generalized thromboembolism. Three dogs survived for 6-25 months. Three dogs alive at the time of this report have survived 22-48 months; however, all 3 dogs have had bacterial infections that responded to antibiotic therapy. There was no biochemical evidence of acute allograft rejection in any dog. Perioperative use of enoxaparin may have prevented thromboembolism in 5 dogs.


CONCLUSIONS
Triple drug immunosuppressive therapy used in this study prevented acute renal allograft rejection in 6 dogs that survived >4 weeks; however, immunosuppression was excessive, resulting in an unacceptable frequency of infection and other drug-related complications. Perioperative anticoagulation therapy seem to be warranted.


CONCLUSIONS
Survival time and quality of life for this group of dogs was poor; however, there was no evidence of acute rejection in the dogs surviving >4 weeks. This protocol should only be used if the degree of immunosuppression is reduced, and early evidence of allograft rejection is monitored by renal biopsy or markers of lymphocyte activation.
Comparative Transplantation Laboratory, Department of Surgical and Radiological Sciences and Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616-8475, USA. cgregory@ucdavis.edu
Clare R
CR
Gregory
Andrew E
AE
Kyles
Lynda
L
Bernsteen
Margo
M
Mehl
D000818:Animals; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D004283:Dog Diseases / Q000453:epidemiology / Q000401:mortality; D004285:Dogs / Q000601:surgery*; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000662:veterinary; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000662:veterinary*; D008297:Male; D009392:Nephrectomy / Q000662:veterinary; D011183:Postoperative Complications / Q000453:epidemiology / Q000401:mortality / Q000662:veterinary; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies; D011788:Quality of Life; D015996:Survival Rate; D013923:Thromboembolism / Q000453:epidemiology / Q000401:mortality / Q000662:veterinary; D014181:Transplantation Immunology; D014184:Transplantation, Homologous / Q000662:veterinary; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine